CN103977059A - Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof - Google Patents
Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof Download PDFInfo
- Publication number
- CN103977059A CN103977059A CN201410207101.6A CN201410207101A CN103977059A CN 103977059 A CN103977059 A CN 103977059A CN 201410207101 A CN201410207101 A CN 201410207101A CN 103977059 A CN103977059 A CN 103977059A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- dog
- special
- liquid
- intravenous nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a special vein nutrient supporting liquid for treating a hundestaupe virus and parvovirus infected dog. The liquid contains heat (carbohydrates and lipid emulsion), necessary and unnecessary amino acids, vitamins, electrolytes and trace elements; besides, the liquid is also added with deoxyglucose, sargassum fusiforme polysaccharide and oleuropein with an immunity regulating function so that the basic nutritional condition of the infected dog can be still maintained even when the infected dog cannot eat foods, and the resistance to diseases is enhanced, thus the aim of increasing the cure rate of the hundestaupe virus and parvovirus infected dog and reducing deaths can be achieved.
Description
Technical field
The invention belongs to animal field of medicaments, relate to canine distemper virus and parvovirus infections dog nutritional support special-purpose intravenous nutrition liquid, particularly a kind of intravenous nutrition liquid and using method thereof that is specifically designed to canine distemper virus and parvovirus infections dog nutritional support.
Background technology
Canine distemper, is commonly called as Canis familiaris L. pestilence, and English name is Canine distemper, is the serious dog class disease of a kind of main harm pup.Its pathogen is canine distemper virus.Sick dog take that to present two-phase pattern of fever, rhinitis, serious digestive disorder and respiratory inflammation etc. be feature, and encephalitis can occur minority case.Canine parvovirus disease is by the caused a kind of acute infectious disease of Canine parvovirus infection pup.Have clinically two kinds of Phenotypes, hemorrhagic enteritis type is significantly reduced to principal character with violent vomiting, hemorrhagic enteritis and leukocyte; Myocarditis type be take sudden death as feature.Canine distemper and Canine Parvovirus be the clinical manifestation of that type no matter, all take that sickness rate is high, mortality rate is high and infectiousness is by force feature, and wherein canine distemper and parvovirus are respectively the first and second common large diseases of dog, and cure rate is very little.
The symptom contact of canine distemper is varied, and in viral virulence, environmental condition, age and immune state are relevant.50%～70% CDV infects and shows as inferior clinical symptom, performance asthenia, anorexia, fervescence and upper respiratory tract infection.Serious symptom canine distemper infects is more common in the not pup of immunity inoculation.The symptom that canine distemper starts is fervescence, continues 1-3 days.Then disappear, the feature very seemingly throwing off a cold.But body temperature raises again after several days, the persistent period is indefinite.Shed tears as seen, eye conjunctiva is rubescent, discharge of eye becomes sticky purulence by aqueous.Asoscope is dry, has nose liquid stream to go out, and starting is serosity nose liquid, after become purulence nose liquid.Sick just have dry cough, after transfer cough caused by pathogenic damp to, dyspnea.The appearance vomiting of the intestines and stomach type, diarrhoea, intestinal intussusception, finally with serious dehydration and decline and death.Nervous symptoms hundstaupe, mostly above-mentioned symptom 7～21 days, occur also there is the person that shows as nervous symptoms at the very start, pup diaplacental infection can produce at 28 days～42 days nervous symptoms, because canine distemper virus infringement central nervous system's position is different, symptom is difference to some extent.Virus is damaged in brain, shows as epilepsy, turn-takes, stance is abnormal, other nervous symptoms such as paroxysmal tic appear in instability of gait, ataxia, masticatory muscles and extremity, and the prognosis of this kind of nerve hundstaupe mostly is bad.Mortality rate pup reaches 80～90%, and adult dogs can reach 40～50%.Canine distemper virus can cause part dog ocular damage, and take clinically conjunctivitis, keratitis is feature, and keratitis is common in latter 15 days left and right of morbidity mostly, and cornea bleaches, and corneal ulcer, perforation, blind can appear in severe one.And generally in 3-14 days, there is Signs after dog contact parvovirus, average disease time is 5-7 days.Clinical symptoms comprises: appetite declines, depressed, heating, vomiting, diarrhoea.Adult dogs starts not necessarily to occur fever phenomenon, and often occur that appetite declines, spirit is depressed, vomiting, diarrhoea (occurring after 24 hours), hyperemesis, feces are thin repeatedly sometimes, are spurting or occur bloody stool.Adult dogs mortality rate is 2-3%.Pup (because high dehydration causes shock) mortality rate reaches 25-50%.
For these two kinds of diseases, fluid infusion is as soon as possible one of committed step for the treatment of, but conventional fluid infusion is clinically mainly to supplement glucose for general house pet doctor, but because composition is single, can not meet the daily nutrition demand of suffering from dog, nutritional support effect is limited, cannot effectively improve Abwehrkraft des Koepers, cause mortality rate higher.
Summary of the invention
The object of this invention is to provide and a kind ofly for distemper virus and parvovirus infections dog special immune, regulate intravenous nutrition to support liquid, by meeting, suffer from dog daily nutrition needs, improve its Abwehrkraft des Koepers, and reach raising cure rate, reduce mortality rate object.
Object of the present invention realizes in the following manner:
The special-purpose intravenous nutrition of a kind of canine distemper virus and parvovirus infections dog is supported liquid, the special-purpose intravenous nutrition of preparation 1000mL is supported liquid, comprise following effective ingredient: 10～15g soybean oil, 10～15g medium chain triglycerides, 1.5～3g lecithin, 2～4g glycerol, the former powder of 20～30g amino acid 20AA, 8～15g N (2)-L-alanyl-L-glutamy, 50～100g glucose, 1～2g potassium chloride, 3～6g fish oil, 0.8～1.2g sodium glycerophosphate, 20～30mg deoxyglucose, the cleupin of 30～40mg, 20～30mg Hijiki polysaccharide, water soluble vitamins comprises: vitamin B1 is 1～2mg, vitamin B2 is 1.5～2mg, nicotiamide 15～25mg, vitamin B6 is 1.5～2.5mg, vitamin C is 40～60mg, vitamin B12 is 2.0～3.0 μ g, fatsoluble vitamin comprises: vitamin A is 0.3～0.6mg, and vitamin D is 2.0～3.0 μ g, and vitamin E is 25～35mg, and vitamin K is 0.05～0.1mg, filtering with microporous membrane degerming, now with the current.
The special-purpose intravenous nutrition of described canine distemper virus and parvovirus infections dog is supported liquid, preferably prepares the special-purpose intravenous nutrition of 1000mL and supports liquid, comprises following effective ingredient: 12.5g soybean oil, 12.5g medium chain triglycerides, 3g lecithin, 3.5g glycerol, the former powder of 25g amino acid 20AA, 10g N (2)-L-alanyl-L-glutamy, 75g glucose, 1.5g potassium chloride, 5g fish oil, 1.08g sodium glycerophosphate, 20mg deoxyglucose, 30mg cleupin, 20mg Hijiki polysaccharide; Water soluble vitamins comprises: vitamin B1 is that 1.5mg, vitamin B2 are 1.8mg, nicotiamide 20mg, and vitamin B6 is 2.0mg, and vitamin C is 50mg, and vitamin B12 is 2.5 μ g; Fatsoluble vitamin comprises: vitamin A is 0.5mg, and vitamin D is 2.5 μ g, and vitamin E is 30mg, and vitamin K is 0.075mg; Filtering with microporous membrane degerming, now with the current.
The special-purpose intravenous nutrition of described canine distemper virus and parvovirus infections dog is supported liquid, preferably prepares the special-purpose intravenous nutrition of 1000mL and supports liquid, comprises following effective ingredient: 13g soybean oil, 13g medium chain triglycerides, 2.1g lecithin, 3g glycerol, the former powder of 30g amino acid 20AA, 15g N (2)-L-alanyl-L-glutamy, 80g glucose, 1.6g potassium chloride, 6g fish oil, 1.2g sodium glycerophosphate, 30mg deoxyglucose, 40mg cleupin, 30mg Hijiki polysaccharide; Water soluble vitamins comprises: vitamin B1 is that 2mg, vitamin B2 are 2mg, nicotiamide 25mg, and vitamin B6 is 2.5mg, and vitamin C is 60mg, and vitamin B12 is 3 μ g; Fatsoluble vitamin comprises: vitamin A is 0.6mg, and vitamin D is 3 μ g, and vitamin E is 35mg, and vitamin K is 0.01mg; Filtering with microporous membrane degerming, now with the current.
The special-purpose intravenous nutrition of described canine distemper virus and parvovirus infections dog is supported the using method of liquid, and the standard that gives 40ml nutritional solution according to trouble dog per kilogram of body weight is carried out venous transfusion.
The present invention is through intravenous route supply canine distemper virus and the needed basic nutrition key element of parvovirus infections dog, comprise heat (carbohydrate, lipomul), essential and non essential amino acid, vitamin, electrolyte and trace element, having added in addition the deoxyglucose with immunoloregulation function makes to suffer from dog still can maintain basic nutrition situation under the situation that cannot normally take food, build up one's resistance to disease, thereby reach, improve canine distemper virus and parvovirus infections dog cure rate, reduce dead object.
The soybean oil adding in the present invention, medium chain triglycerides, lecithin and glycerol mainly provide energy as lipomul.Medium chain triglyceride can be removed quickly than long chain triglyceride from blood, and oxidative function quickly, is therefore more suitable for providing energy for body.Polyunsaturated fatty acid is provided by soybean oil, prevents from lacking because of essential fatty acid the symptom occurring.In lecithin, containing phosphorus, is the constituent of biofilm structure, for guaranteeing mobility and the biological function of film.Glycerol can participate in energy i (in vivo) metabolism, or glycogen biosynthesis and fat.
Amino acid in the present invention (20AA), has comprised 20 kinds of necessary fatty acids, and the nutrition of equalization can be provided, and corrects rapidly negative nitrogen balance.It,, the in the situation that of Power supply abundance, can enter histiocyte, participates in the anabolism of protein, obtains positive nitrogen balance, and generates enzyme, hormone, antibody, structural protein, promotes organization healing, thereby recovers the normal physiological function of body.
N in the present invention (2)-L-alanyl-L-glutamy, discharges aminopropanamide and glutamine after entering in body, can act on intestinal cell, increases the content of thickness, DNA and the protein of intestinal mucosa, maintains the integrity of intestinal mucosa.And can keep the deposit of liver glutathion, can improve the nitrogen balance of body, also can increase body defence capability, prevent and alleviate severe infections, minimizing stress time muscle glutamine loss, wound healing.
Glucose in the present invention provides energy as carbohydrate for body.
Potassium chloride in the present invention is used for treating and prevents in advance dog due to the hypokalemia of vomitting and diarrhoea causes.
Water soluble vitamins (vitamin B1, vitamin B2, nicotiamide, vitamin B6, vitamin C, vitamin B12) contained in the present invention is suffered from the daily physiological need of dog to water soluble vitamins in order to meet.
In the present invention, contained fatsoluble vitamin (vitamin A, vitamin D, vitamin E, vitamin K) is suffered from dog every day to fatsoluble vitamin physiological need for meeting.
The long-chain omega-fatty acid that in the present invention, fish oil provides can be used as blood plasma and the ingredient of organizing lipid.Wherein DHA is the important composition composition of membrane phospholipid structure; EPA is the synthetic precursor substance of eicosane class (as prostaglandin, thromboxane, interleukin and other lipid mediums), and the increase that its medium analog derivative is synthetic, can promote anticoagulant and antiinflammatory action, adjusting immunologic function.
In the present invention, contained sodium glycerophosphate is suffered from the phosphorus supplement of dog intravenous nutrition, in order to meet, suffers from the dog body every day of the needs to phosphorus.
In the present invention, contained deoxyglucose can improve immunosuppressant and the immunodeficiency that animal is caused by various viral infection, can obviously improve immunologic function and the resistance of body.
In the present invention, contained Hijiki polysaccharide is from full algae Sargassum fusiforme (Harv.) Setch, to extract a kind of water soluble polysaccharide obtaining, and mainly contains Algin and sulfated fucan and forms.Modern pharmacology research shows that Hijiki polysaccharide reaches the effect of enhancing human body immunity power by improving cellular immune function.
In the present invention, contained cleupin is the Plant Extracts from olive tree, possesses the effect of antioxidation and booster immunization system.
The specific embodiment
Embodiment 1.
12.5g soybean oil, 12.5g medium chain triglycerides, 3g lecithin, 3.5g glycerol, 25g amino acid (20AA) (purchased from Shenzhen Tai Er amino acid bio Products Co., Ltd), 10g N (2)-L-alanyl-L-glutamy (purchased from Jinan Chenghui Shuangda Chemical Co., Ltd.), 75g glucose, 1.5g potassium chloride, (vitamin B1 is 1.5mg to water soluble vitamins, vitamin B2 is 1.8mg, nicotiamide 20mg, vitamin B6 is 2.0mg, vitamin C is 50mg, vitamin B12 is 2.5 μ g), (vitamin A is 0.5mg to fatsoluble vitamin, vitamin D is 2.5 μ g, vitamin E is 30mg, vitamin K is 0.075mg), 5g fish oil, 1.08g sodium glycerophosphate, 20mg deoxyglucose, 30mg cleupin, 20mg Hijiki polysaccharide.Mentioned component is dissolved in to the intravenous fluid that is mixed with 1000ml in distilled water, 0.45 μ m filtering with microporous membrane degerming, now with the current.
Clinical trial:
Laboratory animal selected for 12～24 monthly ages, and the ill dog that clinical definite is parvovirus, by experimental dog isolated rearing, and be divided at random 3 groups, 20 every group, 3 groups of feeding environments are identical, all take conventional therapy, experiment is carried out 10 days altogether, and wherein matched group provides 10% glucose intravenous fluid; Intravenous nutrition liquid group 1 adopts the special-purpose intravenous nutrition liquid of people [to comprise 20% lipomul (Intralipid, Intralipid) 250ml, aminoacid (7% all lives, Vamin) 1250ml, 50% glucose 400ml, 10% glucose 1000ml, 11.2% sodium lactate 30ml, 10% potassium chloride 40ml, sodium glycerophosphate (lattice row FOX Glycophos) 10ml, 1 bottle of Soluvit, (9 kinds of Soluvit N containing water-soluble vitamin), Vitalipid N Adult (Vitalipid N is containing 4 kinds of fatsoluble vitamiies) 10ml]; The special-purpose intravenous nutrition formula of liquid of intravenous nutrition liquid group 2 application dog of the present invention.It is only all per kilogram of body weight 40ml nutritional solutions that usage is respectively organized dog, once a day.Computational methods: mortality rate=dead animal number/laboratory animal number * 100%, cure rate=healing number of animals/laboratory animal number * 100%.Result (testing the 10th day) when following table is experiment end
| Group | Mortality rate % | Cure rate % | Cure rate not |
| Matched group (10% glucose) | 50 | 15 | 35 |
| Intravenous nutrition treatment group 1 (people uses) | 40 | 25 | 35 |
| Intravenous nutrition treatment group 2 (dog is used) | 25 | 55 | 20 |
Clinical effectiveness statistical analysis, intravenous nutrition treatment group 2 is compared difference extremely significantly (P<0.01) with matched group with intravenous nutrition treatment group 1
Embodiment 2. is by liposoluble substance: 12.5g soybean oil, 12.5g medium chain triglycerides, 2.1g lecithin, 3.5g glycerol, (vitamin A is 0.5mg to fatsoluble vitamin, and vitamin D is 2.5 μ g, and vitamin E is 30mg, vitamin K is 0.075mg), after 5g fish oil mixes, 0.45 μ m filtering with microporous membrane degerming makes A liquid, by water-soluble substances: 25g amino acid (20AA) (purchased from Shenzhen Tai Er amino acid bio Products Co., Ltd), 10g N (2)-L-alanyl-L-glutamy (purchased from Jinan Chenghui Shuangda Chemical Co., Ltd.), 75g glucose, 1.5g potassium chloride, (vitamin B1 is 1.5mg to water soluble vitamins, vitamin B2 is 1.8mg, nicotiamide 20mg, vitamin B6 is 2.0mg, vitamin C is 50mg, vitamin B12 is 2.5 μ g), 1.08g sodium glycerophosphate, deoxyglucose 20mg, cleupin 30mg, 20mg Hijiki polysaccharide is dissolved in and in distilled water, is mixed with 950ml solution, 0.45 μ m filtering with microporous membrane degerming makes B liquid.A liquid and B liquid are placed in respectively 4 ℃ of preservations, mix and use before use.
Embodiment 3.13g soybean oil, 13g medium chain triglycerides, 2.1g lecithin, 3g glycerol, 30g amino acid (20AA) (purchased from Shenzhen Tai Er amino acid bio Products Co., Ltd), 15g N (2)-L-alanyl-L-glutamy (purchased from Jinan Chenghui Shuangda Chemical Co., Ltd.), 80g glucose, 1.6g potassium chloride, (vitamin B1 is 2mg to water soluble vitamins, vitamin B2 is 2mg, nicotiamide 25mg, vitamin B6 is 2.5mg, vitamin C is 60mg, vitamin B12 is 3 μ g), (vitamin A is 0.6mg to fatsoluble vitamin, vitamin D is 3 μ g, vitamin E is 35mg, vitamin K is 0.01mg), 6g fish oil, 1.2g sodium glycerophosphate, 30mg deoxyglucose, 40mg cleupin, 30mg Hijiki polysaccharide.Mentioned component is dissolved in to the intravenous fluid that is mixed with 1000ml in distilled water, 0.45 μ m filtering with microporous membrane degerming, now with the current.
Clinical trial:
Laboratory animal selected for 3～6 monthly ages, clinical definite is the ill dog of canine distemper, by experimental dog isolated rearing, and be divided at random 3 groups, 20 every group, 3 groups of feeding environments are identical, experiment is carried out 10 days altogether, all take conventional therapy, experiment is carried out 10 days altogether, and wherein matched group provides 10% glucose intravenous fluid; Intravenous nutrition liquid group 1 adopts the special-purpose intravenous nutrition liquid of people [to comprise 20% lipomul (Intralipid, Intralipid) 250ml, aminoacid (7% all lives, Vamin) 1250ml, 50% glucose 400ml, 10% glucose 1000ml, 11.2% sodium lactate 30ml, 10% potassium chloride 40ml, sodium glycerophosphate (lattice row FOX Glycophos) 10ml, 1 bottle of Soluvit, (9 kinds of Soluvit N containing water-soluble vitamin), Vitalipid N Adult (VitalipidN is containing 4 kinds of fatsoluble vitamiies) 10ml]; The special-purpose intravenous nutrition formula of liquid of intravenous nutrition liquid group 2 application dog of the present invention.It is only all per kilogram of body weight 40ml nutritional solutions that usage is respectively organized dog, once a day.Computational methods: mortality rate=dead animal number/laboratory animal number * 100%, cure rate=healing number of animals/laboratory animal number * 100%.Following table be experiment while finishing result (testing the 10th day)
| Group | Mortality rate % | Cure rate % | Cure rate not |
| Matched group (10% glucose) | 55 | 10 | 35 |
| Intravenous nutrition treatment group 1 (people uses) | 40 | 30 | 30 |
| Intravenous nutrition treatment group 2 (dog is used) | 20 | 55 | 25 |
Clinical effectiveness statistical analysis, intravenous nutrition treatment group 2 is compared significant difference (P<0.05) safety experiment with matched group with intravenous nutrition treatment group 1:
Choose the healthy dogs at 12 monthly ages, according to the continuous venoclysis of the embodiment of the present invention 1 nutritional solution that configures 30 days, observation experiment dog was without any bad or Deviant Behavior during this period of time, and the drinking-water of searching for food is normal.
Above embodiments of the invention are had been described in detail, but described content is only preferred embodiment of the present invention, can not be considered to for limiting scope of the present invention.All equalization variations of making according to the present patent application scope and change etc., all should belong to patent covering scope of the present invention.
Claims (4)
1. the special-purpose intravenous nutrition of a canine distemper virus and parvovirus infections dog is supported liquid, it is characterized in that, the special-purpose intravenous nutrition of preparation 1000mL is supported liquid, comprise following effective ingredient: 10～15g soybean oil, 10～15g medium chain triglycerides, 1.5～3g lecithin, 2～4g glycerol, the former powder of 20～30g amino acid 20AA, 8～15g N (2)-L-alanyl-L-glutamy, 50～100g glucose, 1～2g potassium chloride, 3～6g fish oil, 0.8～1.2g sodium glycerophosphate, 20～30mg deoxyglucose, the cleupin of 30～40mg, 20～30mg Hijiki polysaccharide, water soluble vitamins comprises: vitamin B1 is 1～2mg, vitamin B2 is 1.5～2mg, nicotiamide 15～25mg, vitamin B6 is 1.5～2.5mg, vitamin C is 40～60mg, vitamin B12 is 2.0～3.0 μ g, fatsoluble vitamin comprises: vitamin A is 0.3～0.6mg, and vitamin D is 2.0～3.0 μ g, and vitamin E is 25～35mg, and vitamin K is 0.05～0.1mg, filtering with microporous membrane degerming, now with the current.
2. according to the special-purpose intravenous nutrition of the canine distemper virus described in claim 1 and parvovirus infections dog, support liquid, it is characterized in that, the special-purpose intravenous nutrition of preparation 1000mL is supported liquid, comprise following effective ingredient: 12.5g soybean oil, 12.5g medium chain triglycerides, 3g lecithin, 3.5g glycerol, the former powder of 25g amino acid 20AA, 10g N (2)-L-alanyl-L-glutamy, 75g glucose, 1.5g potassium chloride, 5g fish oil, 1.08g sodium glycerophosphate, 20mg deoxyglucose, 30mg cleupin, 20mg Hijiki polysaccharide; Water soluble vitamins comprises: vitamin B1 is that 1.5mg, vitamin B2 are 1.8mg, nicotiamide 20mg, and vitamin B6 is 2.0mg, and vitamin C is 50mg, and vitamin B12 is 2.5 μ g; Fatsoluble vitamin comprises: vitamin A is 0.5mg, and vitamin D is 2.5 μ g, and vitamin E is 30mg, and vitamin K is 0.075mg; Filtering with microporous membrane degerming, now with the current.
3. according to the special-purpose intravenous nutrition of the canine distemper virus described in claim 1 and parvovirus infections dog, support liquid, it is characterized in that, the special-purpose intravenous nutrition of preparation 1000mL is supported liquid, comprise following effective ingredient: 13g soybean oil, 13g medium chain triglycerides, 2.1g lecithin, 3g glycerol, the former powder of 30g amino acid 20AA, 15g N (2)-L-alanyl-L-glutamy, 80g glucose, 1.6g potassium chloride, 6g fish oil, 1.2g sodium glycerophosphate, 30mg deoxyglucose, 40mg cleupin, 30mg Hijiki polysaccharide; Water soluble vitamins comprises: vitamin B1 is that 2mg, vitamin B2 are 2mg, nicotiamide 25mg, and vitamin B6 is 2.5mg, and vitamin C is 60mg, and vitamin B12 is 3 μ g; Fatsoluble vitamin comprises: vitamin A is 0.6mg, and vitamin D is 3 μ g, and vitamin E is 35mg, and vitamin K is 0.01mg; Filtering with microporous membrane degerming, now with the current.
4. the special-purpose intravenous nutrition of the canine distemper virus described in claim 1-3 any one and parvovirus infections dog is supported the using method of liquid, it is characterized in that, the standard that gives 40ml nutritional solution according to trouble dog per kilogram of body weight is carried out venous transfusion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410207101.6A CN103977059A (en) | 2014-05-15 | 2014-05-15 | Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410207101.6A CN103977059A (en) | 2014-05-15 | 2014-05-15 | Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103977059A true CN103977059A (en) | 2014-08-13 |
Family
ID=51269386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410207101.6A Pending CN103977059A (en) | 2014-05-15 | 2014-05-15 | Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103977059A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190129450A (en) * | 2018-05-11 | 2019-11-20 | 조선대학교산학협력단 | Composition comprising extract of Sargassum fusiforme for preventing or treating influenza |
| CN111919975A (en) * | 2020-08-24 | 2020-11-13 | 四川水利职业技术学院 | Health product for improving dog nose wettability and preparation method thereof |
-
2014
- 2014-05-15 CN CN201410207101.6A patent/CN103977059A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| 周圣贤等: "全胃肠外营养在犬瘟热治疗中的应用", 《中国兽医杂志》 * |
| 李杰女等: "羊栖菜多糖药用活性的研究进展", 《亚太传统医药》 * |
| 潘启超: "选择性抗疱疹病毒药物的分子基础与药理学考虑", 《广州医药》 * |
| 郝婷等: "橄榄苦苷提取分离和药理活性的研究进展", 《承德医学院学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190129450A (en) * | 2018-05-11 | 2019-11-20 | 조선대학교산학협력단 | Composition comprising extract of Sargassum fusiforme for preventing or treating influenza |
| KR102070040B1 (en) | 2018-05-11 | 2020-01-29 | 조선대학교산학협력단 | Composition comprising extract of Sargassum fusiforme for preventing or treating influenza |
| CN111919975A (en) * | 2020-08-24 | 2020-11-13 | 四川水利职业技术学院 | Health product for improving dog nose wettability and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rahimi et al. | Effect of the three herbal extracts on growth performance, immune system, blood factors and intestinal selected bacterial population in broiler chickens | |
| Reque et al. | Inflammation induced by inactivated Aeromonas hydrophila in Nile tilapia fed diets supplemented with Saccharomyces cerevisiae | |
| US10398715B2 (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
| CN115350200A (en) | Synthetic compositions for the treatment of metabolic disorders | |
| CN106942748A (en) | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof | |
| US20120277316A1 (en) | Methods and compositions for treating and preventing parenteral nutrition associated liver disease | |
| Adeshina et al. | Dietary Mitracarpus scaber leaves extract improved growth, antioxidants, non-specific immunity, and resistance of Nile tilapia, Oreochromis niloticus to Gyrodactylus malalai infestation | |
| Awuchi et al. | Bioactive compounds and therapeutics from fish: revisiting their suitability in functional foods to enhance human wellbeing | |
| CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
| CN106858595A (en) | One kind burn tailored version clinical nutrition formula and preparation method thereof | |
| Zhong et al. | Phytic acid disrupted intestinal immune status and suppressed growth performance in on-growing grass carp (Ctenopharyngodon idella) | |
| CN105901703B (en) | Marine organism type enteral nutrition preparation for burn patients | |
| CN103190483A (en) | Children growth promotion milk tea | |
| Hasanthi et al. | Dietary niacin requirement of Pacific white shrimp (Litopenaeus vannamei) | |
| Gutyj et al. | Influence of amprolinsile and brovitacoccid on the protein synthesizing function of the liver and enzyme activity in turkey blood serum during Eimeria invasion | |
| Ji et al. | β-glucan mitigated trinitrobenzene sulfonic acid-induced enteritis in the rainbow trout (Oncorhynchus mykiss) | |
| JP2015504042A (en) | Use of flaxseed-derived cyclic peptides to improve animal and human health | |
| Laela et al. | The effect of kefir-spirulina on glycemic status and antioxidant activity in hyperglycemia rats. | |
| Cheng et al. | Lactobacillus casei-fermented blueberry pomace ameliorates colonic barrier function in high fat diet mice through MAPK-NF-κB-MLCK signaling pathway | |
| CN103977059A (en) | Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof | |
| Kataoka et al. | A Review of foods and food supplements increasing testosterone levels | |
| DE69031694T3 (en) | Glutamine for the treatment of impaired immunity | |
| Abozaid et al. | Nutritional Effect of Using a Bioactive Mixture (Lemon, Onion and Garlic) on Growth Performances, Feed Utilization, Immune Status and Gene Expression of Nile tilapia (Oreochromis niloticus) | |
| Liu et al. | Dietary effect of ferulic acid on growth performance, physiological response, non-specific immunity and disease resistance of oriental river prawn (Macrobrachium nipponense) | |
| CN104524568B (en) | A kind of pharmaceutical composition for treating obesity and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140813 |
|
| RJ01 | Rejection of invention patent application after publication |